ArticleAntimicrobial agents and chemotherapy2018
Effect of Genetic Variation of
Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 34 citations in OpenAlex.
- Pharmacogenetic Study of Anti-TB Drugs in the Native Ancestry Peruvian Population.Pharmacology research & perspectives · 2025Article
- Pharmacogenetic variability of tuberculosis biomarkers in native and mestizo Peruvian populations.Pharmacology research & perspectives · 2024Article
- Variability in plasma rifampicin concentrations and role ofInfectious diseases (London, England) · 2024Article
- Article
- Advancing tuberculosis management: the role of predictive, preventive, and personalized medicine.Frontiers in microbiology · 2023Review
- Pharmacogenetic testing for NAT2 genotypes in a Tanzanian population across the lifespan to guide future personalized isoniazid dosing.Tuberculosis (Edinburgh, Scotland) · 2022Article
- Genetic Variants and Drug Efficacy in Tuberculosis: A Step toward Personalized Therapy.Global medical genetics · 2022Review
- Effect of Genetic Variations in Drug-Metabolizing Enzymes and Drug Transporters on the Pharmacokinetics of Rifamycins: A Systematic Review.Pharmacogenomics and personalized medicine · 2022Review
- Pharmacogenomics of drug transporters for antiretroviral long-acting pre-exposure prophylaxis for HIV.Frontiers in genetics · 2022Review
- Transporter and metabolizer gene polymorphisms affect fluoroquinolone pharmacokinetic parameters.Frontiers in pharmacology · 2022Review
- Observational
- Genetic Diversity in Drug Transporters: Impact in African Populations.Clinical and translational science · 2020Review
- Influence of Single Nucleotide Polymorphisms on Rifampin Pharmacokinetics in Tuberculosis Patients.Antibiotics (Basel, Switzerland) · 2020Review
- Role of Genetic Variations in the Hepatic Handling of Drugs.International journal of molecular sciences · 2020 · on this mapReview
- A review of clinical pharmacogenetics Studies in African populations.Personalized medicine · 2020Review
- Drug-Drug Interactions of Infectious Disease Treatments in Low-Income Countries: A Neglected Topic?Clinical pharmacology and therapeutics · 2019Review
- Current research toward optimizing dosing of first-line antituberculosis treatment.Expert review of anti-infective therapy · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 8 institutions in 3 countries.
Funding
Abstract
Isoniazid and rifampin are essential components of first-line antituberculosis (anti-TB) therapy. Understanding the relationship between genetic factors and the pharmacokinetics of these drugs could be useful in optimizing treatment outcomes, but this is understudied in children. We investigated the relationship between N-acetyltransferase type 2 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.